Leadership

ClearNote Health has built a world-class multi-disciplinary team focused on applying our unique epigenomic platform to make long-term cancer survival a reality for more people.

I am inspired by scaling truly innovative companies centered around the most urgent patient needs. With a laser focus on science and corporate development, companies can thrive while improving patient lives.

Dave Mullarkey

Chief Executive Officer

Dave is a life sciences industry veteran with an extensive track record of success across the life sciences industry of scaling and delivering value with therapeutic, diagnostic, and life science tools companies in both private and public settings. Most recently, he was president and chief executive officer of Omniome, where he guided and scaled the DNA sequencing company from the early technology development stage through the delivery of its beta prototype leading to its sale to PacBio in 2021. Prior to Omniome, Dave served as the president and chief operating officer of Ariosa Diagnostics, a global diagnostics company focused on using cell-free DNA in non-invasive prenatal testing that was acquired by Roche in 2014. Post-acquisition, Dave served as lifecycle leader, site head, and a core member of the Roche Sequencing Solutions leadership team. He has also held positions at Johnson & Johnson, Eli Lilly and Company, Valeant Pharmaceuticals, and Dow Pharmaceuticals Sciences.

I am inspired by scaling truly innovative companies centered around the most urgent patient needs. With a laser focus on science and corporate development, companies can thrive while improving patient lives.
Translating complex biology and technology into valuable patient-centric products is what excites me the most.

Samuel Levy, PhD

Chief Scientific Officer

Samuel joined ClearNote Health at its inception and has co-authored many of the research papers we have published about our epigenomics technology platform and our DNA-based 5-hydroxymethylcytosine (5hmC) biomarker. For more than 20 years, he has held leadership positions in genomics and molecular diagnostic development at companies including Celera, Genomic Health, Quanticel Pharmaceuticals (now part of Celgene), and Impact Genomics/Lexent Bio which he co-founded and is now a part of Foundation Medicine. Samuel has also served on the faculty at the J. Craig Venter Institute, Scripps Translational Science Institute and Scripps Research Institute. He holds degrees from the University of Bristol and the University of Leeds in the United Kingdom.

Translating complex biology and technology into valuable patient-centric products is what excites me the most.
I feel privileged to help the ClearNote Health team develop breakthrough technologies to improve patient care.

Wayne Volkmuth, PhD

Senior Vice President, Informatics & Data Discovery

Wayne has more than 20 years of experience in bioinformatics, genomics and drug discovery. He cofounded Atreca and Innectus, and held leadership positions at Renovis (now part of Evotec), Ceres, and Incyte Pharmaceuticals. Wayne has been granted US patents and has co-authored multiple peer-reviewed publications. He holds degrees from Stanford University, Princeton University, and University of Minnesota.

I feel privileged to help the ClearNote Health team develop breakthrough technologies to improve patient care.
Working at ClearNote Health since its inception, I continue to be inspired and motivated by the common goal I share with my incredibly talented colleagues: to help make all cancers treatable through early detection.

Anna Bergamaschi, PhD

Vice President, Product Development

Anna has over a decade of experience in next-generation sequencing assay workflows and has worked as a senior scientist at ClearNote Health. Previously, at Genomic Health, she led the technical development of blood-based liquid biopsy assay. Anna holds a PhD in Molecular Oncology from the University of Oslo, Norway in collaboration with Stanford where she spent most of her time in the optimization of array CGH. She holds a Master’s in Medical Biotechnology from the University of Modena School of Medicine, Italy.

Working at ClearNote Health since its inception, I continue to be inspired and motivated by the common goal I share with my incredibly talented colleagues: to help make all cancers treatable through early detection.
It's paramount that we make cutting-edge medical innovations accessible to patients whose lives can be prolonged through early diagnosis of cancer.

Danielle Scelfo, MHSA

Vice President, Market Access & Health Policy

Danielle is an accomplished health policy strategist who has led teams across government affairs, market access, and reimbursement functions for over 25 years. Her extensive subject matter expertise guided innovative payment reforms across precision medicine diagnostics during her tenure at Sanofi Aventis, Genomic Health, Adaptive Biotechnologies, and Hologic. A principal voice in diagnostic health policy, Danielle has chaired the Coalition for 21st Century Medicine Reimbursement and Policy Workgroup, the California Healthcare Institute Diagnostic Workgroup, and participated in several CPT working groups for the American Medical Association. A member of leading federal and state diagnostic trade associations, Danielle earned her Master’s in Health Administration at Florida International University and a Bachelor of Science in Marketing from the University of Florida.

It's paramount that we make cutting-edge medical innovations accessible to patients whose lives can be prolonged through early diagnosis of cancer.
Cancer has affected or will affect everyone very personally in their lifetimes. I am thrilled to have the opportunity to apply my technology expertise in life sciences to ClearNote Health's cancer detection mission.

Eric Nilson

Vice President, Enterprise IS&T

Eric has more than 20 years of experience directing IT for life sciences companies including Response Genetics Inc., Cypress Bioscience Inc., Suneva Medical Inc., and Orchestra Therapeutics Inc. He holds a B.S. in Business Administration/Information and Decision Systems from San Diego State University. He also served in the U.S. Marine Corps.

Cancer has affected or will affect everyone very personally in their lifetimes. I am thrilled to have the opportunity to apply my technology expertise in life sciences to ClearNote Health's cancer detection mission.
Driven by passion for patients, we are committed to using our combined scientific, clinical, and automation expertise to help physicians detect cancers early, when their patients can still be treated.

Shimul Chowdhury, PhD, FACMG

Vice President, Laboratory Operations

Shimul has served as a clinical laboratory director in multiple laboratories including Rady Children’s Institute for Genomic Medicine (RCIGM), Illumina Inc. and Quest Diagnostics. He has dedicated his career to implementing new genomic technologies to improve patient care and outcomes. He is a board-certified clinical molecular geneticist and licensed as a laboratory director in California, Florida and New York. He has authored over 30 peer-reviewed publications.

Driven by passion for patients, we are committed to using our combined scientific, clinical, and automation expertise to help physicians detect cancers early, when their patients can still be treated.

Alan Ashworth PhD, FRS

  • Cancer biomarkers and therapeutics, DNA repair/synthetic lethality
  • President, Helen Diller Comprehensive Cancer Center
  • SVP for Cancer Services, UCSF Health
  • Professor, Hematology Oncology, UCSF

David A. Diamond, MD, FACRO

  • Clinical advisor to ClearNote since inception
  • More than 20 years of clinical oncology experience
  • Former Chair of the Florida Board of Medicine
  • Former Chancellor of the American College of Radiation Oncology
  • Princeton University A.B. & University of Florida M.D.
  • Post-graduate training at Yale and Washington University St. Louis

Felix Feng, MD

  • Radiation oncology leader in translational research
  • Significant expertise in identifying and treating aggressive prostate cancer
  • Director, Translational Genomics at University of Michigan, Ann Arbor

Stephen Quake, D. Phil

  • Pioneer in liquid biopsy, single cell genomics, microfluidics
  • Head of Science, Chan Zuckerberg Initiative (CZI)
  • Professor, Bioengineering and applied physics Stanford University
  • Member of all three National Academies – Science, Engineering, and Medicine
  • Past Investigator, Howard Hughes Medical Institute

Maximilian Schmid, MD

  • Board-certified physician, seasoned strategic thinker, and accomplished healthcare executive with a proven track record.
  • Experienced C-Suite executive leader who has implemented successful growth strategies at CENTOGENE AG, Roche Sequencing Solutions, Ariosa Diagnostics, and McKinsey & Company.
  • Maternal-Fetal Medicine expert, clinical genetics thought leader, and former Associate Professor at the prestigious Medical University of Vienna, Austria.

J. Craig Venter, PhD

  • Pioneer in sequencing Human Genome at Celera Genomics
  • Pioneer in genomic medicine, founder of Human Longevity Inc.
  • Founder of J. Craig Venter Institute (JCVI)

Mattias Westman

  • International finance and investments
  • Founding Partner, Prosperity Capital Management
  • Active global cross-border investor
  • Stockholm School of Economics

Stephen Quake, D. Phil

  • Pioneer in liquid biopsy, single cell genomics, microfluidics
  • Head of Science, Chan Zuckerberg Initiative (CZI)
  • Professor, Bioengineering and applied physics Stanford University
  • Member of all three National Academies – Science, Engineering, and Medicine
  • Past Investigator, Howard Hughes Medical Institute

Tina S. Nova, PhD

  • Pioneer in molecular-based diagnostics in oncology
  • President and CEO, Decipher Biosciences (acquired Veracyte)
  • Former President and CEO, Genoptix (acquired Novartis)
  • Prior executive leadership positions, Molecular Stethoscope, Illumina and Nanogen
  • Biotechnology leadership Ligand Pharmaceuticals, Hybritech

Dave Mullarkey

  • Life Sciences industry leader with an extensive track record of success in the cell free DNA diagnostics space, DNA sequencing instrument development, and operating in CLIA and IVD environment
  • Proven executive track record of C-level leadership scaling life sciences companies globally to successful exits across pharmaceuticals, diagnostics and life science tools
  • Most recent roles included President and CEO at Omniome, President and COO at Ariosa Diagnostics and Lifecycle Leader and Site Head at Roche
  • Decades of growth-oriented executive experience across different sizes and stages of companies both private and public (Omniome, Roche, Ariosa Diagnostics, Valeant Pharmaceuticals, Johnson & Johnson, Eli Lilly and Company, Dow Pharmaceuticals).

Join Our Team and
Make a Difference